June 24, 2025

Liraglutide Linked to Fewer Migraine Days

A small observational study found that liraglutide, a GLP-1 receptor agonist typically used to treat diabetes and support weight loss, significantly reduced migraine frequency in adults with a BMI of 30 or higher—independent of weight change.

Conexiant

June 23, 2025

Nightmares Linked to Faster Aging, Early Death: Study

A large study has found that frequent nightmares in adults are linked to faster biological aging and a significantly higher risk of dying before age 75, highlighting a potential warning sign for long-term health risks.

Conexiant

June 11, 2025

Does Paracetamol Block Peripheral Pain?

A newly published study showed that a metabolite of paracetamol can directly block sodium channels in peripheral pain-sensing neurons, helping reduce pain without acting on the brain.

Conexiant

June 06, 2025

FDA Monthly Round-up: Key May Updates

May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.

Conexiant

June 04, 2025

Medical Oddities: Legumes Over Lipids?

From ticklish brains to bean-powered cholesterol drops, here’s what made the medical rounds weirdly wonderful this week.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 28, 2025

Fremanezumab Cuts Migraine, Depression Burden in Trial

Fremanezumab reduced monthly migraine days and improved depression scores compared with placebo.

Conexiant

May 27, 2025

Rizatriptan Shows No Rapid Relief for Vertigo

A randomized trial found that rizatriptan 10 mg did not significantly reduce vertigo or dizziness within 1 hour during vestibular migraine attacks, though some symptom improvements were seen at 24 hours.

Conexiant

April 28, 2025

One Third Report HPPD After Psychedelics

Delusional ideation was found to be reduced one month after psychedelic use, researchers reported in a prospective cohort of 654 participants.

Conexiant